Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer worldwide and despite optimized cytotoxic therapies, the 5-year survival rate of metastatic disease remains poor. Novel targets and therapies are clearly needed for disseminated disease. Receptor tyrosine kinases (RTKs) are attractive cancer targets due to: 1) frequent deregulation via mutation, amplification and/or autocrine/paracrine activation, 2) proximal positioning in oncogenic signal pathways and 3) specific targeting by small molecule tyrosine kinase inhibitors (TKIs) and inhibitory antibodies. To date, targeted therapies have not been effectively applied to HNSCC due, in part, to paucity of information on the dominant oncogene drivers. While the inhibitory EGFR antibody, cetuximab, is approved for use in HNSCC, overall effects are modest, likely due to failure to select for EGFR-addicted HNSCCs and/or rapid acquisition of resistance. While genomic approaches provide new information regarding tumor suppressors relevant to HNSCC, frequently mutated oncogene drivers were not generally identified. This observation raises the question of whether targeted therapeutics can, in fact, be successfully applied to this cancer. Our published findings identify a subset of HNSCC cell lines that is highly sensitive to FGFR inhibitors as well as a subset that is sensitive to EGFR-specific TKIs. In addition, our published and preliminary findings reveal putative roles for FGFRs in acquired resistance to EGFR-specific inhibitors. Together, these results support a hypothesis that an FGFR autocrine pathway is a dominant oncogene driver in a subset of HNSCCs. Moreover, specific FGFRs are candidates for acquired or intrinsic resistance mechanisms to EGFR inhibitors in HNSCC. To test these hypotheses, we will complete these Aims:
Aim 1. Define the active FGFRs and FGFs that function as drivers in HNSCC cell lines and in primary HNSCC tumors directly propagated in nude mice. Also, the prevalence of FGFR pathway expression in archived HNSCC tumors will be defined. We will test the hypothesis that FGFR1 and specific FGFs and proteoglycan co-receptors are components of an oncogene driver pathway that functions in a clinically relevant fraction of head and neck tumors.
Aim 2. Define FGFR-dependent and novel mechanisms of resistance to EGFR inhibitors in HNSCC. Our studies show rapid induction of FGFR2 and FGFR3 in EGFR- dependent HNSCC cells following treatment with EGFR-specific inhibitors as well as slower adaptive induction of FGFR1 and FGF2 during acquired resistance of EGFR-dependent HNSCC cell lines to gefitinib. We hypothesize that the failure of EGFR-targeted therapies to provide long-term control of HNSCC is due to multiple auxiliary growth pathways that reduce efficacy of EGFR inhibition alone. Completion of these specific aims is anticipated to unveil FGFR pathways as novel therapeutic targets in HNSCC. The ongoing early clinical development of multiple FGFR inhibitors could set the stage for their rapid application to this cancer that is highly relevant to the veteran population.
Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequently occurring cancer worldwide with one of the lowest cancer associated five-year survival rates. While effectiveness of standard cytotoxic therapies have been optimized, novel targeted inhibitors against the Epidermal Growth Factor Receptor (EGFR) have shown some additional clinical benefit in head and neck cancer patients. However, these therapies are not curative, largely due to the limited initial responses and invariable tumor relapse due to resistance to the drugs. Our findings reveal novel roles for Fibroblast Growth Factor Receptors (FGFRs) as oncogene drivers in a subset of HNSCC cell lines. In addition, FGFRs also appear to function in acquired resistance to EGFR-targeted agents. Our proposal will molecularly define these roles for FGFRs in HNSCC cell lines and develop predictive biomarkers of FGFR activity in primary tumor specimens, thereby setting the stage for rapid advancement of clinical trials using FGFR inhibitors in HNSCC patients.
|Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60|
|von Mässenhausen, Anne; Sanders, Christine; Thewes, Britta et al. (2016) MERTK as a novel therapeutic target in head and neck cancer. Oncotarget 7:32678-94|
|von Mässenhausen, Anne; Deng, Mario; Billig, Hannah et al. (2016) Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Target Oncol 11:631-642|
|Kleczko, Emily K; Kim, Jihye; Keysar, Stephen B et al. (2015) An Inducible TGF-?2-TGF?R Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. PLoS One 10:e0123600|
|Göke, Friederike; Franzen, Alina; Hinz, Trista K et al. (2015) FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. Clin Cancer Res 21:4356-64|
|Singleton, Katherine R; Hinz, Trista K; Kleczko, Emily K et al. (2015) Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Res 75:4398-406|
|Schröck, Andreas; Bode, Maike; Göke, Friederike Johanna Maria et al. (2014) Expression and role of the embryonic protein SOX2 in head and neck squamous cell carcinoma. Carcinogenesis 35:1636-42|
|Göke, Friederike; Bode, Maike; Franzen, Alina et al. (2013) Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck. Mod Pathol 26:1298-306|
|von Mässenhausen, Anne; Franzen, Alina; Heasley, Lynn et al. (2013) FGFR1 as a novel prognostic and predictive biomarker in squamous cell cancers of the lung and the head and neck area. Ann Transl Med 1:23|
|Singleton, Katherine R; Kim, Jihye; Hinz, Trista K et al. (2013) A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and ne Mol Pharmacol 83:882-93|